David Sinclair's Age-Reversal Trial: What It Actually Tests (And Does Not)

Age reversal: David Sinclair's company has dosed the first human with epigenetic reprogramming. The trial is real, it is first-in-human, and its primary endpoint is safety.

On January 15, 2026 the FDA authorized it. On June 9 a patient received an injection into one eye, carrying instructions to partially reset the age of the cells inside it. It is the first time partial epigenetic reprogramming has been tried in a human being.

So what do we actually know? Less than the headlines suggest, and more than you would think.

The trial is ER-100, from Life Biosciences, co-founded by Harvard geneticist David Sinclair. He is the principal in this story, not a commentator on it, and this video says so up front. It enrolls 18 people. It lists 21 primary outcome measures, and every one of them is safety. It is not designed to answer whether age reversal works.

This walks what actually happened, in order: the 2020 Nature mouse result, the primate data, the FDA authorization, the first dose. Then what the registry actually commits to measuring. Then the part worth knowing: why they used 3 of the 4 Yamanaka factors instead of all 4, and why the therapy only runs while the patient takes an antibiotic. The most interesting thing in the first human age-reversal trial is not the reprogramming. It is the off switch.

VERIFICATION: Checked August 5, 2026. NO Phase 1 results have been published. ClinicalTrials.gov NCT07290244 reports has Results = false, status RECRUITING. If that has changed by the time you are watching, this video describes the period before the first readout.

What you'll learn:
• What the FDA actually authorized, and when
• The 2020 Nature result: OSK restores vision in mice
• Why the primate data is solid but unpublished
• 18 patients, 21 primary endpoints, all safety
• Why c-Myc was left out, and what the doxycycline switch does
• How to read any early result: ask what the study was designed to find out

Chapters:
00:00 FDA clears the first age-reversal trial
01:29 The 2020 Nature study that restored vision in mice
04:13 What the ER-100 trial actually is: 18 patients, 21 safety endpoints
06:43 The off switch: 3 Yamanaka factors, not 4
09:26 Evidence tiers: mouse, primate, human safety
11:02 What "age reversal" actually means here
12:49 How to read an early trial result
13:49 A question, not a verdict

SOURCES (all primary, retrieved 2026-08-04):
1. Lu Y, Brommer B, Tian X, ... He Z, Sinclair DA. "Reprogramming to recover youthful epigenetic information and restore vision." Nature 2020;588(7836):124-129. PMID 33268865
2. Nakagawa M, ... Yamanaka S. "Generation of induced pluripotent stem cells without Myc from mouse and human fibroblasts." Nature Biotechnology 2008;26:101-106. PMID 18059259
3. ClinicalTrials.gov NCT07290244. Phase 1, ER-100 in optic neuropathies. Estimated enrollment 18. Primary outcomes: safety and tolerability
4. Life Biosciences. FDA clearance of the IND (announced January 28, 2026) and first patient dosed (June 9, 2026)
5. Life Biosciences. Nonhuman primate data presented at the AAO Annual Meeting, Chicago, October 2024. Conference presentation, not peer-reviewed

RELATED:
• Rapamycin and the line one scientist draws: https://youtu.be/li2fhq-tI8A
• Metformin and exercise, what that drug actually does: https://youtu.be/B3FByxo8xH8

Music by Maksim Chubrey from Pixabay: https://pixabay.com/users/cozyvibes-25452378/

Images: David Sinclair and FDA photographs supplied by the channel owner. Laboratory and molecular imagery under the Pixabay Content License.

This video is for general education only and is not medical advice, and it is not a recommendation to take any drug or supplement. The compound discussed may be a prescription medicine; any use for aging or longevity is off-label and not approved for that purpose. No drug is approved anywhere for extending human lifespan. Nothing here is a dose, a protocol, or sourcing guidance. Do not start, stop, or change any medication or supplement without a doctor who knows your health.

From The Longevity Experts. We rank longevity compounds and habits by how strong the evidence actually is, and we say so out loud. No supplement ads, no hype, no fear-mongering, just the honest ranking. Subscribe for evidence-first longevity, ranked.